Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial

Jayant S Vaidya¹, Max Bulsara², Samuele Massarut³, Elena Sperk⁴, Frederik Wenz⁵, Jeffrey S Tobias⁶; TARGIT-A trial authors

Affiliations

¹ University College London, London, UK. Electronic address: jayant.vaidya@ucl.ac.uk.
² University of Notre Dame, Fremantle, WA, Australia.
³ Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy.
⁴ Department of Radiation Oncology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
⁵ University of Freiburg Hospital, Freiburg, Germany.
⁶ University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 34197756
DOI: 10.1016/S1470-2045(21)00278-3

Comment

Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial

Jayant S Vaidya et al. Lancet Oncol. 2021 Jul.

. 2021 Jul;22(7):e295-e296.

doi: 10.1016/S1470-2045(21)00278-3.

Authors

Jayant S Vaidya¹, Max Bulsara², Samuele Massarut³, Elena Sperk⁴, Frederik Wenz⁵, Jeffrey S Tobias⁶; TARGIT-A trial authors

Affiliations

¹ University College London, London, UK. Electronic address: jayant.vaidya@ucl.ac.uk.
² University of Notre Dame, Fremantle, WA, Australia.
³ Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy.
⁴ Department of Radiation Oncology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
⁵ University of Freiburg Hospital, Freiburg, Germany.
⁶ University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 34197756
DOI: 10.1016/S1470-2045(21)00278-3

No abstract available

PubMed Disclaimer

Conflict of interest statement

JSV reports grants from the Health Technology Assessment Programme of the UK National Institute of Health Research; and honoraria and travel support from Carl Zeiss. MB reports honoraria and travel support from Carl Zeiss. SM reports travel support from Carl Zeiss. ES reports grants from the German Ministry of Science and Arts; and travel support and honoraria from Carl Zeiss. JST reports honoraria and travel support from Carl Zeiss; and grants from the Health Technology Assessment Programme of the UK National Institute of Health Research. All competing interests are outside of the submitted work. FW declares no competing interests.

Comment in

Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial - Authors' reply.
Orecchia R, Maisonneuve P, Leonardi MC. Orecchia R, et al. Lancet Oncol. 2021 Jul;22(7):e298. doi: 10.1016/S1470-2045(21)00355-7. Lancet Oncol. 2021. PMID: 34197758 No abstract available.

Comment on

Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.
Orecchia R, Veronesi U, Maisonneuve P, Galimberti VE, Lazzari R, Veronesi P, Jereczek-Fossa BA, Cattani F, Sangalli C, Luini A, Caldarella P, Venturino M, Sances D, Zurrida S, Viale G, Leonardi MC, Intra M. Orecchia R, et al. Lancet Oncol. 2021 May;22(5):597-608. doi: 10.1016/S1470-2045(21)00080-2. Epub 2021 Apr 9. Lancet Oncol. 2021. PMID: 33845035 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial

Affiliations

Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources